Protagenic Therapeutics, Inc.\new EPS History: Annual & Quarterly (PTIX)
Protagenic Therapeutics, Inc.\new's diluted EPS was $0.59 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2026 | 2026-03-31 | $0.59 | $0.59 | $1.26 | — |
| 2025 | 2025-03-31 | -$0.67 | -$0.67 | — | — |
| 2024 | 2024-12-31 | -$15.82 | -$15.82 | $0.28 | — |
| 2023 | 2023-12-31 | -$16.10 | -$16.10 | -$4.62 | — |
| 2022 | 2022-12-31 | -$11.48 | -$11.48 | $5.88 | — |
| 2021 | 2021-12-31 | -$17.36 | -$17.36 | -$3.36 | — |
| 2020 | 2020-12-31 | -$14.00 | -$14.00 | -$4.48 | — |
| 2019 | 2019-12-31 | -$9.52 | -$9.52 | $4.48 | — |
| 2018 | 2018-12-31 | -$14.00 | -$14.00 | -$1.68 | — |
| 2017 | 2017-12-31 | -$12.32 | -$12.32 | $11.76 | — |
| 2016 | 2016-12-31 | -$24.08 | -$24.08 | -$15.68 | — |
| 2015 · Dec 31 | 2015-12-31 | -$8.40 | -$8.40 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $0.00 | $0.00 | $0.00 | — |
| 2014 | 2014-06-30 | $0.00 | $0.00 | — | — |
Protagenic Therapeutics, Inc.\new quarterly diluted eps
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | -$0.53 | -$0.53 | $0.84 | — |
| Q3 2026 | 2025-12-31 | $1.14 | $1.14 | $1.30 | — |
| Q2 2026 | 2025-09-30 | -$0.47 | -$0.47 | -$0.36 | — |
| Q1 2026 | 2025-06-30 | -$1.37 | -$1.37 | -$1.31 | — |
| Q4 2025 | 2025-03-31 | -$2.75 | -$2.75 | $2.69 | — |
| Q4 2024 | 2024-12-31 | -$0.16 | -$0.16 | — | — |
| Q3 2024 | 2024-09-30 | -$0.11 | -$0.11 | $4.37 | — |
| Q2 2024 | 2024-06-30 | -$0.06 | -$0.06 | $3.86 | — |
| Q1 2024 | 2024-03-31 | -$5.44 | -$5.44 | -$3.06 | — |
| Q3 2023 | 2023-09-30 | -$4.48 | -$4.48 | -$1.54 | — |
| Q2 2023 | 2023-06-30 | -$3.92 | -$3.92 | -$1.82 | — |
| Q1 2023 | 2023-03-31 | -$2.38 | -$2.38 | — | — |
| Q3 2022 | 2022-09-30 | -$2.94 | -$2.94 | -$0.14 | — |
| Q2 2022 | 2022-06-30 | -$2.10 | -$2.10 | $4.06 | — |
| Q3 2021 | 2021-09-30 | -$2.80 | -$2.80 | $2.80 | — |
| Q2 2021 | 2021-06-30 | -$6.16 | -$6.16 | -$2.80 | — |
| Q1 2021 | 2021-03-31 | -$6.16 | -$6.16 | -$3.36 | — |
| Q3 2020 | 2020-09-30 | -$5.60 | -$5.60 | -$5.04 | — |
| Q2 2020 | 2020-06-30 | -$3.36 | -$3.36 | -$1.68 | — |
| Q1 2020 | 2020-03-31 | -$2.80 | -$2.80 | $0.56 | — |
| Q3 2019 | 2019-09-30 | -$0.56 | -$0.56 | $2.24 | — |
| Q2 2019 | 2019-06-30 | -$1.68 | -$1.68 | $2.24 | — |
| Q1 2019 | 2019-03-31 | -$3.36 | -$3.36 | $0.00 | — |
| Q3 2018 | 2018-09-30 | -$2.80 | -$2.80 | -$0.56 | — |
| Q2 2018 | 2018-06-30 | -$3.92 | -$3.92 | -$1.68 | — |
| Q1 2018 | 2018-03-31 | -$3.36 | -$3.36 | $0.00 | — |
| Q3 2017 | 2017-09-30 | -$2.24 | -$2.24 | $1.12 | — |
| Q2 2017 | 2017-06-30 | -$2.24 | -$2.24 | $2.24 | — |
| Q1 2017 | 2017-03-31 | -$3.36 | -$3.36 | $2,955.12 | — |
| Q3 2016 | 2016-09-30 | -$3.36 | -$3.36 | $0.56 | — |
| Q2 2016 | 2016-06-30 | -$4.48 | -$4.48 | -$3.36 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | -$2,958.48 | -$2,958.48 | -$2,958.48 | — |
| Q4 2015 | 2015-12-31 | $0.00 | $0.00 | $0.00 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | -$3.92 | -$3.92 | -$3.92 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | -$1.12 | -$1.12 | — | — |
| Q3 2015 | 2015-03-31 | $0.00 | $0.00 | $0.00 | — |
| Q2 2015 | 2014-12-31 | $0.00 | $0.00 | $0.00 | — |
| Q1 2015 | 2014-09-30 | $0.00 | $0.00 | $0.00 | — |
| Q3 2014 | 2014-03-31 | $0.00 | $0.00 | — | — |
| Q2 2014 | 2013-12-31 | $0.00 | $0.00 | — | — |
| Q1 2014 | 2013-09-30 | $0.00 | $0.00 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | -$40.32 | -$40.32 | -$1.12 | — |
| Q2 2011 · Jun 30 | 2011-06-30 | -$54.32 | -$54.32 | -$6.16 | — |
| Q3 2011 · Sep 30 | 2010-09-30 | -$39.20 | -$39.20 | — | — |
| Q2 2011 · Jun 30 | 2010-06-30 | -$48.16 | -$48.16 | — | — |
Protagenic Therapeutics, Inc.\new diluted eps trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's diluted eps increased from $0.00 to $0.59, a change of $0.59. The latest reported quarter, Q1 2027, shows -$0.53.
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗